This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Novel Therapeutic Options in PAH: Addressing Complex Cases and Emerging Research

Novel Therapeutic Options in PAH: Addressing Complex Cases and Emerging Research



Time to Complete

30 minutes


August 15, 2018


August 15, 2019
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider

Sponsored by the Academy for Continued Healthcare Learning.

Commercial Supporter

This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., and Bayer HealthCare Pharmaceuticals Inc.

Program Description

In this video-based interview, Dan Schuller, MD, reviews emerging management and therapeutic models for pulmonary arterial hypertension (PAH) treatment. Dr. Schuller addresses adverse therapeutic events, strategies for complex PAH cases, and related clinical trial data for both current and emerging PAH therapies. He additionally discusses advanced-practice strategies related to PAH disease classification, risk stratification, and therapeutic selection criteria, especially for complex PAH cases. This is the first in a series of two educational activities on PAH to be released in 2018.

Intended Audience

This activity is designed for primary care physicians, cardiologists, cardiopulmonologists, and other allied healthcare professionals interested in PAH.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate recent changes and updates to the disease classifications/risk stratifications of PAH and related therapeutics
  • List emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans across at-risk populations
  • Evaluate causes of complex and mixed PH and related referral/treatment strategies

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.


Dan Schuller, MD
Chair and Professor,
Department of Internal Medicine Texas Tech University Health Sciences Center in El Paso– Transmountain
Paul L. Foster School of Medicine
El Paso, TX

Dr. Schuller discloses the following
Speakers' Bureau: Bayer HealthCare Pharmaceuticals Inc., Gilead Sciences, Inc.

Staff Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Bardoxolone methyl (Phase III)


The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


To obtain credit, a score of 66% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Laurie Novoryta


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue